Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group (VSports手机版)
- PMID: 3883504
"V体育官网入口" Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group
Abstract
In two multicenter studies, 325 patients with advanced squamous lung cancer were randomized to receive either no treatment v oral etoposide (VePe-sid) 300 mg/m2 on days 1 and 2 for 6 cycles, or the same dose of oral etoposide v the same dose of oral etoposide plus cyclophosphamide 300 mg/m2 IV on days 1 and 2, each given for 6 cycles. A total of 175 patients in both trials received oral etoposide alone VSports手机版. All patients assigned to treatment were included in the results. Remissions occurred in 20 (11%) patients (CR in 1; PR in 19). Leukopenia occurred in 2% of patients and other toxicity was acceptable. .
Publication types
- V体育ios版 - Actions
MeSH terms
- "V体育官网入口" Actions
Substances
- "V体育2025版" Actions
LinkOut - more resources
Medical
V体育官网入口 - Research Materials